Evaluation of neuromodulatory effects of caffeine and nootropics on dopamine metabolism and neuropeptide expression
Research platform investigating how caffeine and nootropic compounds influence dopamine metabolism, related enzymatic pathways, and hypothalamic neuropeptides involved in learning and memory. Offers in vitro validation using hypothalamic cell models under oxidative and inflammatory stress, with HPLC-EC analytics and bioinformatics support.
Overview
This research offering evaluates the neuromodulatory effects of caffeine and nootropic compounds on dopamine metabolism and related neuropeptide expression in hypothalamic cells. The work addresses how these substances influence dopamine turnover, key catabolic enzymes, and neuropeptides linked to learning, memory, and behavioral function. By combining cellular assays with oxidative and pro-inflammatory challenge models, the program provides a controlled environment to assess neuroprotective and cognitive-enhancing properties of candidate compounds.
Technical specifications
Research capabilities include:
- In vitro stimulation of hypothalamic HypoE22 cells with caffeine and nootropics under basal and stress conditions
- Measurement of dopamine, L-DOPA, HVA, and DOPAC levels using HPLC with electrochemical detection
- Gene expression analysis of tyrosine hydroxylase, MAO-B, and COMT to characterize dopamine synthesis and catabolism
- Evaluation of hypothalamic neuropeptides involved in behavioral functions, including BDNF, Orexins, and NPY
- Bioinformatics analyses incorporating network pharmacology and molecular docking to identify compound-target interactions
Technology readiness level
The research is at an early-to-mid stage of preclinical validation, building on existing evidence of caffeine's neuroprotective and neuromodulatory effects. Future validation steps are defined and include standardized cellular stimulation protocols, analytical quantification of dopamine pathway intermediates, and computational target analysis. The approach is positioned to support proof-of-concept studies for nutraceutical, pharmaceutical, and cognitive health applications.
About Universita degli Studi Gabriele d'Annunzio di Chieti e Pescara
Università degli Studi “Gabriele d’Annunzio” Chieti–Pescara is a comprehensive public university serving the Abruzzo region, with two campuses and an affiliated teaching hospital. Co‑located clinical, preclinical, and analytical facilities enable industry to prototype, validate, and scale with academic partners. The university maintains structured pathways for collaboration, including sponsored research, contract services, student placements, and tailored short courses coordinated through central liaison offices. Research draws on competitive European and Italian support, including Horizon Europe, national ministries, and regional innovation programs. A dedicated technology transfer office manages IP, licensing, spin‑outs, and collaboration agreements, and helps companies access shared instrumentation.
Inquire about this partnering listing
Available for
Industry applications
delivered to your inbox.